New research shows that eliminating Treg cells that prevent the cancer-fighting effect of an immunotherapy treatment doesn't actually end their suppressive qualities.
Treg cell activity suppresses the immune response and therefore stops the cancer-fighting effect of the immunotherapy treatments; however, eliminating the Treg cells does not end their suppressive qualities, according to new research.
In a study recently published in Nature Immunology, researchers investigated the effects of immune cell activity that may limit immunotherapy’s effectiveness. T cells fight the infection and Treg cells send the signal to the T cells to stop fighting the threat. Immunotherapies super-charge the immune system to fight the cancer, and when the Tregs come in to suppress the immune response, they also stop the cancer-fighting effect.
The researchers found that eliminating the Treg cells does not provide any benefits to patients and does not eliminate their suppressive qualities, because when the Tregs die they become more suppressive rather than negated.
The study found that when the Treg cells die they release small metabolites called ATP, which help supply energy to the body. The dying Tregs quickly convert the ATP to adenosine which then targets the T-cells—this makes the T cells unhealthy and negatively affects how they function, the study found.
“It’s a double-edged sword: If they do not die, they are suppressive. But if they die, they are even more suppressive,” senior study author Weiping Zou, MD, PhD, Charles B. de Nancrede Professor of surgery, immunology, pathology and cancer biology at the University of Michigan, said in a statement. “Nobody expected this — it was a total surprise. But it likely explains why you don’t see benefit when you induce Treg apoptosis."
Although immunotherapy has demonstrated many benefits and revolutionized cancer treatment, there remains to be many limitations and unanswered questions. The researchers are now looking to limit the negative function of Treg cells by forming a roadblock to stop the cells from migrating to the tumor microenvironment in addition to controlling the suppressive activity.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More